S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
S&P 500   2,978.76 (-4.42%)
DOW   25,766.64 (-4.42%)
QQQ   205.64 (-5.01%)
AAPL   273.52 (-6.54%)
FB   189.75 (-3.78%)
MSFT   158.18 (-7.05%)
GOOGL   1,314.95 (-5.43%)
AMZN   1,884.30 (-4.81%)
CGC   18.44 (-6.96%)
NVDA   252.60 (-5.62%)
BABA   205.03 (-1.78%)
MU   50.58 (-3.42%)
GE   10.39 (-5.11%)
TSLA   679.00 (-12.81%)
AMD   44.01 (-7.33%)
T   35.73 (-3.69%)
ACB   1.45 (-3.97%)
F   6.97 (-3.33%)
NFLX   371.71 (-1.99%)
PRI   114.78 (-4.46%)
BAC   29.13 (-4.90%)
DIS   118.04 (-4.31%)
GILD   72.66 (-2.73%)
Log in

NASDAQ:LPTX - Leap Therapeutics Stock Price, Forecast & News

$2.62
-0.07 (-2.60 %)
(As of 02/27/2020 04:00 PM ET)
Today's Range
$2.55
Now: $2.62
$2.80
50-Day Range
$1.58
MA: $2.02
$2.90
52-Week Range
$0.57
Now: $2.62
$3.18
Volume518,983 shs
Average Volume1.23 million shs
Market Capitalization$63.39 million
P/E RatioN/A
Dividend YieldN/A
Beta2.24
Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:LPTX
CUSIPN/A
Phone617-714-0360

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$0.62 per share

Profitability

Net Income$-23,140,000.00

Miscellaneous

Employees23
Market Cap$63.39 million
Next Earnings Date4/6/2020 (Estimated)
OptionableNot Optionable

Receive LPTX News and Ratings via Email

Sign-up to receive the latest news and ratings for LPTX and its competitors with MarketBeat's FREE daily newsletter.


Leap Therapeutics (NASDAQ:LPTX) Frequently Asked Questions

What is Leap Therapeutics' stock symbol?

Leap Therapeutics trades on the NASDAQ under the ticker symbol "LPTX."

How were Leap Therapeutics' earnings last quarter?

Leap Therapeutics Inc (NASDAQ:LPTX) released its quarterly earnings results on Thursday, November, 14th. The company reported ($0.33) earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.33). View Leap Therapeutics' Earnings History.

When is Leap Therapeutics' next earnings date?

Leap Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, April 6th 2020. View Earnings Estimates for Leap Therapeutics.

What price target have analysts set for LPTX?

3 brokerages have issued 12-month price objectives for Leap Therapeutics' shares. Their forecasts range from $2.50 to $6.00. On average, they expect Leap Therapeutics' share price to reach $3.92 in the next twelve months. This suggests a possible upside of 49.5% from the stock's current price. View Analyst Price Targets for Leap Therapeutics.

What is the consensus analysts' recommendation for Leap Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Leap Therapeutics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Leap Therapeutics.

Has Leap Therapeutics been receiving favorable news coverage?

Media headlines about LPTX stock have been trending extremely negative recently, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Leap Therapeutics earned a media sentiment score of -4.2 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Leap Therapeutics.

Are investors shorting Leap Therapeutics?

Leap Therapeutics saw a increase in short interest during the month of February. As of February 14th, there was short interest totalling 1,640,000 shares, an increase of 41.4% from the January 30th total of 1,160,000 shares. Based on an average daily volume of 696,600 shares, the short-interest ratio is currently 2.4 days. Currently, 11.3% of the shares of the company are short sold. View Leap Therapeutics' Current Options Chain.

Who are some of Leap Therapeutics' key competitors?

What other stocks do shareholders of Leap Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Leap Therapeutics investors own include Agile Therapeutics (AGRX), Nabriva Therapeutics (NBRV), Sorrento Therapeutics (SRNE), Amarin (AMRN), Anavex Life Sciences (AVXL), Verastem (VSTM), Aduro BioTech (ADRO), Fortress Biotech (FBIO), Pieris Pharmaceuticals (PIRS) and Senseonics (SENS).

Who are Leap Therapeutics' key executives?

Leap Therapeutics' management team includes the folowing people:
  • Dr. Christopher K. Mirabelli Ph.D., CEO, Pres & Chairman (Age 65)
  • Mr. Douglas E. Onsi J.D., CFO, Gen. Counsel, Treasurer & Sec. (Age 50)
  • Mr. Augustine J. Lawlor, Chief Operating Officer (Age 63)

Who are Leap Therapeutics' major shareholders?

Leap Therapeutics' stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (2.73%). View Institutional Ownership Trends for Leap Therapeutics.

Which major investors are selling Leap Therapeutics stock?

LPTX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC. View Insider Buying and Selling for Leap Therapeutics.

How do I buy shares of Leap Therapeutics?

Shares of LPTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Leap Therapeutics' stock price today?

One share of LPTX stock can currently be purchased for approximately $2.62.

How big of a company is Leap Therapeutics?

Leap Therapeutics has a market capitalization of $63.39 million. The company earns $-23,140,000.00 in net income (profit) each year or ($2.51) on an earnings per share basis. Leap Therapeutics employs 23 workers across the globe.View Additional Information About Leap Therapeutics.

What is Leap Therapeutics' official website?

The official website for Leap Therapeutics is http://www.leaptx.com/.

How can I contact Leap Therapeutics?

Leap Therapeutics' mailing address is 47 THORNDIKE STREET SUITE B1-1, CAMBRIDGE MA, 02141. The company can be reached via phone at 617-714-0360.


MarketBeat Community Rating for Leap Therapeutics (NASDAQ LPTX)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  232 (Vote Outperform)
Underperform Votes:  219 (Vote Underperform)
Total Votes:  451
MarketBeat's community ratings are surveys of what our community members think about Leap Therapeutics and other stocks. Vote "Outperform" if you believe LPTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LPTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel